

Cryotherapy

a therapeutic option for metastatic lung tumors



Galil Medical's ultra-thin 1.5 mm cryotherapy needles provide precise ablation for treating metastatic lung cancer¹

Cryotherapy has unique radiographic visibility of the ablation zone¹⁻⁶ that:

- Provides real-time control over the extent of ablation⁷
- Allows intra-procedural adjustment to minimize damage near critical structures⁸
- Delivers iceball images that correlate with the pathologic zone of ablation^{6,9}





Image courtesy of **Thierry T. de Baere, MD**
Departments of Surgical Oncology and Interventional Radiology
Institut de Cancérologie Gustave Roussy, Villejuif, France

Percutaneous cryotherapy for metastatic tumors provides:

- Local control rate of 80% at a median 21 months¹⁰
- One year survival of 89.4%¹⁰

Percutaneous Cryotherapy of Metastatic Pulmonary Lesions
Local Progression-free Rate¹¹



Cryotherapy has an established safety profile^{4,7,8} with low rates of severe complications¹² and self-limiting side effects¹³:

Complication Rates Following Percutaneous Cryoablation of Metastatic Lung Tumors

Author	Severe Complications \geq CTCAE 3	Pneumothorax (% requiring chest tube insertion)	Self-Limited Hemoptysis	Pleural Effusion
Pusceddu et al. ¹	0%	21% (0%)	0%	0%
Wang et al. ¹³	N/A	12% (12%)	62%	14%
Kawamura et al. ¹⁰	0%	50% (4.5%)	36.4%	27%
Inoue et al. ⁴	3%	61.7% (10.9%)	36.8%	70.5%
Bang et al. ¹²	8%	N/A	N/A	N/A

Cryotherapy is minimally invasive^{1,14} and:

- Is an alternative for nonsurgical candidates⁴
- May result in a short hospital stay^{1,15,16}
- Demonstrates no loss of pulmonary function, measured at six month post ablation follow-up¹⁵
- Offers improved quality of life, with an increased mean Karnofsky Performance Scale score¹³

Cryotherapy offers multiple benefits:

- Allows use of multiple needles simultaneously⁶ for:
 - Optimized tumor coverage⁸
 - Treating a range of tumor sizes^{5,8,12,17}
- Produces less procedural pain than RF ablation^{5,8,17}
- Does not require use of grounding pads⁵
- Compared to RF, results in a higher rate of complete ablation for tumors ≤ 3 cm¹⁸
- Can be performed under local anesthesia or conscious sedation^{1,8,14}

References

1. Pusceddu C, Sotgia B, Fele RM, Melis L. CT-guided thin needles percutaneous cryoablation (PCA) in patients with primary and secondary lung tumors: A preliminary experience. *Eur J Radiol* 2013; 24:229-233.
2. Gilliams A. Tumor ablation: current role in the kidney, lung and bone. *Cancer Imag* 2009; 9: S68-S70.
3. Hinshaw JL, Littrup PJ, Durick N, et al. Optimizing the Protocol for Pulmonary Cryoablation: A Comparison of a Dual- and Triple-Freeze Protocol. *Cardiovasc Intervent Radiol* 2010; 33: 1180-1185.
4. Inoue M, Nakatsuka S, Yashiro H, et al. Percutaneous Cryoablation of Lung Tumors: Feasibility and Safety. *J Vasc Interv Radiol* 2012; 23:295-302.
5. McTaggart RA, Dupuy DE. Thermal Ablation of Lung Tumors. *Tech Vasc Interventional Rad* 2007; 10:102-113.
6. Sonntag PD, Hinshaw JL, Lubner MG, et al. Thermal Ablation of Lung Tumors. *Surg Oncol Clin N Am* 2011; 20:369-387.
7. Ahrar K, Littrup P. Is Cryotherapy the Optimal Technology for Ablation of Lung Tumors? *J Vasc Interv Radiol* 2012; 23:303-305.
8. Zhang X, Tian J, Zhao L, et al. CT-guided conformal cryoablation for peripheral NSCLC: Initial experience. *Eur J Radiol* 2012; 81:3354-3362.
9. Hinshaw JL, Lee FT, Laeseke PF, et al. Temperature Isotherms during Pulmonary Cryoablation and their Correlation with the Zone of Ablation. *J Vasc Interv Radiol* 2010; 21:1424-1428.
10. Kawamura M, Izumi Y, Tsukada N, et al. Percutaneous cryoablation of small pulmonary malignant tumors under computed tomographic guidance with local anesthesia for nonsurgical candidates. *J Thorac Cardiovasc Surg* 2006; 131:1007-1013.
11. Yashiro H, Nakatsuka S, Inoue M, et al. Factors Affecting Local Progression after Percutaneous Cryoablation of Lung Tumors. *J Vasc Interv Radiol* 2013; 24:813-821.
12. Bang HJ, Littrup PJ, Currier BP, et al. Percutaneous Cryoablation of Metastatic Lesions from Non-Small-Cell Lung Carcinoma: Initial Survival, Local Control, and Cost Observations. *J Vasc Interv Radiol* 2012; 23:761-769.
13. Wang H, Littrup PJ, Duan Y, et al. Thoracic Masses Treated with Percutaneous Cryotherapy: Initial Experience with More than 200 Procedures. *Radiology* 2005; 235:289-298.
14. Yamauchi Y, Izumi Y, Hashimoto K, et al. Percutaneous Cryoablation for the Treatment of Medically Inoperable Stage I Non-Small Cell Lung Cancer. *PLoS One* 2012; 7: e33223.
15. Zemlyak A, Moore WH, Bilfinger TV. Comparison of Survival after Sublobar Resections and Ablative Therapies for Stage I Non-Small Cell Lung Cancer. *J Am Coll Surg* 2010; 211:68-72.
16. Chen CK, Chou HP, Sheu MH. Image-guided lung tumor ablation: Principal, technique, and current status. *J Chin Med Assoc* 2013; 76:303-311.
17. Jahangeer S, Forde P, Soden D, Hinchion J. Review of current thermal ablation treatment for lung cancer and the potential of electrochemotherapy as a means for treatment of lung tumors. *Cancer Treat Rev* 2013; <http://dx.doi.org/10.1016/j.ctrv.2013.03.007>.
18. Choe YH, Kim SR, Lee KS, et al. The use of PTC and RFA as treatment alternatives with low procedural morbidity in non-small cell lung cancer. *Eur J Cancer* 2009; 45:1773-1779.

This application is not available in all markets

Indications for Use

The Galil Medical Cryoablation Systems are intended for cryoablative destruction of tissue during surgical procedures; various Galil Medical ancillary products are required to perform these procedures. Galil Medical Cryoablation Systems are indicated for use as a cryosurgical tool in the fields of general surgery, dermatology, neurology (including cryoanalgesia), thoracic surgery, ENT, gynecology, oncology, proctology and urology. These Systems are designed to destroy tissue (including prostate and kidney tissue, liver metastases, tumors, and skin lesions) by the application of extremely cold temperatures. A full list of specific indications can be found in the Galil Medical Cryoablation System User Manuals.

Contraindications There are no known contraindications.

Warnings / Precautions / Adverse Events

A thorough understanding of the technical principles, clinical applications, and risks associated with cryoablation procedures is necessary before using Galil Medical products to conduct cryoablation. Use of such products should be restricted to use by or under the supervision of physicians trained in cryoablation procedures with a Galil Medical Cryoablation System.

A full list of the warnings, precautions, and adverse events can be found by referencing the respective device Instructions for Use document or Cryoablation System User Manual.

R_x only

Galil Medical Inc.

4364 Round Lake Road
Arden Hills, MN 55112
USA
Tel: +1 651 287 5000
+1 877 639 2796

Galil Medical Ltd.

Tavor Building 1
Yokneam
Israel 2069203
Tel: +972 (4) 9093200



www.galilmedical.com